专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1997034927A1 ISOLATED DIMERIC FIBROBLAST ACTIVATION PROTEIN ALPHA, AND USES THEREOF 审中-公开
标题翻译：分离的二聚体纤维蛋白激活蛋白ALPHA及其用途
公开(公告)号：WO1997034927A1
公开(公告)日：1997-09-25
申请号：PCT/US1997004215
申请日：1997-03-12
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH , BOEHRINGER INGELHEIM INTERNATIONAL GMBH , ZIMMERMAN, Rainer , PARK, John, E. , RETTIG, Wolfgang , OLD, Lloyd, J.
发明人： LUDWIG INSTITUTE FOR CANCER RESEARCH , BOEHRINGER INGELHEIM INTERNATIONAL GMBH
IPC分类号： C07K14/435
CPC分类号： C12N9/6424 , C07K14/705 , C07K14/70517 , C07K2319/00 , C12N9/48 , C12N2799/026 , C12P21/06
摘要： The invention involves dimeric forms of the protein known as fibroblast activation protein alfpha, or "FAP alpha " and its uses.
摘要翻译：本发明涉及称为成纤维细胞激活蛋白αf或“FAPα”的蛋白质的二聚体形式及其用途。

2. 发明申请

WO2007057397A1 TREATMENT OF CANCER 审中-公开
标题翻译：治疗癌症
公开(公告)号：WO2007057397A1
公开(公告)日：2007-05-24
申请号：PCT/EP2006/068459
申请日：2006-11-14
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , SOMMERGRUBER, Wolfgang , KRAUT, Norbert , SCHWEIFER, Norbert , RETTIG, Wolfgang , HILBERG, Frank , SOLCA, Flavio , STEEGMAIER, Martin
发明人： SOMMERGRUBER, Wolfgang , KRAUT, Norbert , SCHWEIFER, Norbert , RETTIG, Wolfgang , HILBERG, Frank , SOLCA, Flavio , STEEGMAIER, Martin
IPC分类号： A61K31/404 , A61K31/4045 , A61K31/454 , A61K31/4178 , A61K31/496 , A61P35/00
CPC分类号： A61K31/404 , A61K9/0031 , A61K9/02 , A61K9/1652 , A61K9/2077 , A61K31/4045 , A61K31/4178 , A61K31/454 , A61K31/496 , A61K47/02
摘要： The invention is based on the finding that indolinones are useful for the therapy of diseases which result from aberrant activity of certain tyrosine kinases selected from the group comprising ABL, FGFR3, FLT3, and RET.
摘要翻译：本发明基于这样的发现，即吲哚啉酮可用于治疗由选自ABL，FGFR3，FLT3和RET的组中的某些酪氨酸激酶的异常活性引起的疾病。

3. 发明申请

WO0071571A3 FAP-ACTIVATED ANTI-TUMOR COMPOUNDS 审中-公开
标题翻译： FAP活化的抗肿瘤化合物
公开(公告)号：WO0071571A3
公开(公告)日：2001-09-07
申请号：PCT/EP0004261
申请日：2000-05-11
申请人： BOEHRINGER SOHN INGELHEIM , PARK JOHN EDWARD , RETTIG WOLFGANG J , LENTER MARTIN , PETERS STEFAN , MACK JUERGEN , LEIPERT DIETMAR , GARIN CHESA PILAR , FIRESTONE RAYMOND ARMAND , TELAN LEILA A
发明人： PARK JOHN EDWARD , RETTIG WOLFGANG J , LENTER MARTIN , PETERS STEFAN , MACK JUERGEN , LEIPERT DIETMAR , GARIN-CHESA PILAR , FIRESTONE RAYMOND ARMAND , TELAN LEILA A
IPC分类号： A61K31/704 , A61K38/00 , A61K45/00 , A61K47/42 , A61K47/48 , A61P35/00 , A61P43/00 , C07H15/252 , C07K1/06 , C07K1/107 , C07K5/06 , C07K5/062 , C07K5/11 , C07K5/117 , A61K38/04 , C07K9/00
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/65 , A61K47/67 , C07H15/252 , C07K5/06026 , C07K5/1019 , C07K5/1024
摘要： The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP alpha ), said prodrug having a cleavage site which is recognised by FAP alpha , and said drug being cytotoxic or cytostatic under physiological conditions.
摘要翻译：本发明涉及能够通过人成纤维细胞活化蛋白（FAPα）的催化作用转化为药物的前药，所述前药具有被FAPα识别的切割位点，所述药物是细胞毒性或细胞抑制剂生理条件。

4. 发明申请

WO9957151A3 FAP alpha -SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY 审中-公开
标题翻译： FAPα-SPECIFIC抗体具有改善的生产能力
公开(公告)号：WO9957151A3
公开(公告)日：2000-03-16
申请号：PCT/EP9902711
申请日：1999-04-22
申请人： BOEHRINGER INGELHEIM INT , PARK JOHN EDWARD , GARIN CHESA PILAR , BAMBERGER UWE , RETTIG WOLFGANG J , LEGER OLIVIER , SALDANHA JOSE
发明人： PARK JOHN EDWARD , GARIN-CHESA PILAR , BAMBERGER UWE , RETTIG WOLFGANG J , LEGER OLIVIER , SALDANHA JOSE
IPC分类号： G01N33/574 , A61K38/00 , A61K39/395 , A61K47/48 , A61K49/00 , A61K51/10 , A61P35/00 , C07K16/18 , C07K16/40 , C07K16/46 , C07K19/00 , C12N5/10 , C12N15/09 , C12N15/13 , C12N15/62 , C12N15/85 , C12P21/02 , C12Q1/02 , G01N33/577
CPC分类号： C07K16/40 , A61K38/00 , C07K2317/24 , C07K2317/567 , C07K2317/732 , C07K2319/00 , C12N2799/026
摘要： Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP alpha ) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.
摘要翻译：提供重组抗体蛋白质，其特异性结合成纤维细胞活化蛋白α（FAPα）并且包含框架修饰，导致提高宿主细胞的生产性。本发明还涉及所述抗体用于诊断和治疗目的的用途以及产生所述抗体的方法。

5. 发明申请

WO2007057399A2 TREATMENT OF CANCER 审中-公开
标题翻译：治疗癌症
公开(公告)号：WO2007057399A2
公开(公告)日：2007-05-24
申请号：PCT/EP2006068461
申请日：2006-11-14
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , SOMMERGRUBER WOLFGANG , KRAUT NORBERT , SCHWEIFER NORBERT , RETTIG WOLFGANG , HILBERG FRANK , SOLCA FLAVIO , STEEGMAIER MARTIN
发明人： SOMMERGRUBER WOLFGANG , KRAUT NORBERT , SCHWEIFER NORBERT , RETTIG WOLFGANG , HILBERG FRANK , SOLCA FLAVIO , STEEGMAIER MARTIN
IPC分类号： A61P35/00 , A61K31/404
CPC分类号： A61K31/404
摘要： The invention is based on the finding that indolinones are useful for the therapy of diseases which result from aberrant activity of a kinase selected from the group comprising AXL, FLT3, MEK1, and RET.
摘要翻译：本发明基于以下发现：吲哚啉酮可用于治疗由选自包括AXL，FLT3，MEK1和RET的组的激酶的异常活性引起的疾病。

6. 发明申请

WO1995024483A1 RECOMBINANT HUMANIZED ANTI-FB5 ANTIBODIES 审中-公开
标题翻译：重组人类抗体FB5抗体
公开(公告)号：WO1995024483A1
公开(公告)日：1995-09-14
申请号：PCT/US1995003095
申请日：1995-03-08
申请人： SCOTGEN BIOPHARMACEUTICALS, INC. , LUDWIG INSTITUTE FOR CANCER RESEARCH , WALLACE, Thomas, P. , CARR, Francis, J. , RETTIG, Wolfgang, J. , GARIN-CHESA, Pilar , OLD, Lloyd, J. , HARRIS, William, J.
发明人： SCOTGEN BIOPHARMACEUTICALS, INC. , LUDWIG INSTITUTE FOR CANCER RESEARCH
IPC分类号： C12N15/13
CPC分类号： C07K16/30 , C07K2317/24 , C07K2319/00
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.
摘要翻译：本发明提供了针对抗原FB5特异的几种人源化鼠抗体的产生，其被鼠抗体FB5识别。 FB5抗原在广泛恶性肿瘤的血管内皮细胞的腔表面上表达。本发明还提供编码人源化FB5特异性抗体的许多多核苷酸，用于产生人源化FB5特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供使用人源化FB5特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供了使用FB5特异性抗体治疗癌症的方法。

7. 发明申请

WO1995024482A1 RECOMBINANT HUMANIZED ANTI-LK26 ANTIBODIES 审中-公开
标题翻译：重组人类抗LK26抗体
公开(公告)号：WO1995024482A1
公开(公告)日：1995-09-14
申请号：PCT/US1995003094
申请日：1995-03-08
申请人： SCOTGEN BIOPHARMACEUTICALS, INC. , LUDWIG INSTITUTE FOR CANCER RESEARCH , WALLACE, Thomas, P. , HARRIS, William, J. , CARR, Francis, J. , RETTIG, Wolfgang, J. , GARIN-CHESA, Pilar , OLD, Lloyd, J.
发明人： SCOTGEN BIOPHARMACEUTICALS, INC. , LUDWIG INSTITUTE FOR CANCER RESEARCH
IPC分类号： C12N15/13
CPC分类号： G01N33/6854 , G01N33/57484 , G01N33/6833
摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.
摘要翻译：本发明提供了针对抗原LK26特异的几种人源化鼠抗体的产生，其被鼠抗体LK26识别。该抗原在所有绒毛膜癌，畸胎癌和肾癌细胞系中表达，而不在白血病，淋巴瘤，神经外胚层衍生的和上皮性肿瘤细胞系的细胞系（除了上皮细胞系的一小部分之外）上表达。此外，肾癌细胞株表达LK26抗原时，肾上皮细胞不正常。类似地，除了滋养层之外，所有正常的成年和胎儿组织均检测到LK26表型阴性。本发明还提供编码人源化LK26特异性抗体的许多多核苷酸，用于产生人源化LK26特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。本发明还提供了使用人源化LK26特异性抗体检测癌细胞（体外和体内）的方法。另外，本发明提供使用LK26特异性抗体治疗癌症的方法。

8. 发明申请

WO0071571A8 FAP-ACTIVATED ANTI-TUMOR COMPOUNDS 审中-公开
标题翻译： FAP活化的抗肿瘤化合物
公开(公告)号：WO0071571A8
公开(公告)日：2002-03-07
申请号：PCT/EP0004261
申请日：2000-05-11
申请人： BOEHRINGER INGELHEIM PHARMA , PARK JOHN EDWARD , RETTIG WOLFGANG J , LENTER MARTIN , PETERS STEFAN , MACK JUERGEN , LEIPERT DIETMAR , GARIN CHESA PILAR , FIRESTONE RAYMOND ARMAND , TELAN LEILA A
发明人： PARK JOHN EDWARD , RETTIG WOLFGANG J , LENTER MARTIN , PETERS STEFAN , MACK JUERGEN , LEIPERT DIETMAR , GARIN-CHESA PILAR , FIRESTONE RAYMOND ARMAND , TELAN LEILA A
IPC分类号： A61K31/704 , A61K38/00 , A61K45/00 , A61K47/42 , A61K47/48 , A61P35/00 , A61P43/00 , C07H15/252 , C07K1/06 , C07K1/107 , C07K5/06 , C07K5/062 , C07K5/11 , C07K5/117 , A61K38/04 , C07K9/00
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/65 , A61K47/67 , C07H15/252 , C07K5/06026 , C07K5/1019 , C07K5/1024
摘要： The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP alpha ), said prodrug having a cleavage site which is recognised by FAP alpha , and said drug being cytotoxic or cytostatic under physiological conditions.
摘要翻译：本发明涉及能够通过人成纤维细胞活化蛋白（FAPα）的催化作用转化为药物的前体药物，所述前药具有被FAPα识别的切割位点，所述药物是细胞毒性或细胞抑制剂生理条件。

9. 发明申请

WO2007057399A3 TREATMENT OF CANCER WITH INDOLE DERIVATIVES 审中-公开
公开(公告)号：WO2007057399A3
公开(公告)日：2007-05-24
申请号：PCT/EP2006/068461
申请日：2006-11-14
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , SOMMERGRUBER, Wolfgang , KRAUT, Norbert , SCHWEIFER, Norbert , RETTIG, Wolfgang , HILBERG, Frank , SOLCA, Flavio , STEEGMAIER, Martin
发明人： SOMMERGRUBER, Wolfgang , KRAUT, Norbert , SCHWEIFER, Norbert , RETTIG, Wolfgang , HILBERG, Frank , SOLCA, Flavio , STEEGMAIER, Martin
IPC分类号： A61P35/00 , A61K31/404
摘要： The invention is based on the finding that indolinones are useful for the therapy of diseases which result from aberrant activity of a kinase selected from the group comprising AXL, FLT3, MEK1, and RET.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式